Tirzepatide is a single peptide that activates two incretin hormone receptors, GIP and GLP-1. Together these pathways act on appetite, insulin release and blood sugar control.
In the 72-week SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, participants on the highest dose lost an average of 20.9% of their body weight. Tirzepatide is now approved in the UK for type 2 diabetes and weight management.
Each NW Supplements pen is pre-mixed and pre-filled, so there is nothing to reconstitute and no separate kit to buy. Every pen is genuine Alluvi Healthcare stock, manufactured in Germany, with its batch number and expiry date printed on the box and an Alluvi authenticity seal you can check under UV light.
